>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS

October 13 - 17 2012, 12:00 AM - 12:00 AM

ANESTHESIOLOGY 2012

>

FDA MEDWATCH ALERTS

RSS

May 16, 2012

Hydromorphone Hydrochloride Recall

Summary:

Hydromorphone Hydrochloride Recall

April 18, 2012

Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume

Summary:

Customer report of two Carpujects syringes containing more than the 1 mL labeled fill volume. Opioid pain medications such as morphine have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), and low blood pressure.

March 05, 2012

Cardiac Science Powerheart, CardioVive, CardioLife; GE Responder and Responder Pro; and Nihon-Kohden Automated External Defibrillators (AEDs): Class I Recall - Defective Component

Summary: FDA notified healthcare professionals and medical care organizations of the Class 1 recall of the listed AEDs which contain a component that may fail unexpectedly due to a defect. If the component were to fail during a rescue attempt, the AED may not deliver defibrillation therapy, causing serious adverse health consequences, including death. The unit’s self test may not detect the failure or impending failure of the component.

>

ASA FEATURED PRODUCT

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-12CE

... Read more »

Single Copies, Member Price: $300

J&J Announces FDA Rejection of SEDASYS® Device

Chicago — (April 22, 2010) 

On Tuesday April 20, 2010 as reported by several media sources,1 2 Johnson & Johnson, parent company of Ethicon Endo Surgery, Inc., announced that the Food and Drug Administration (FDA) rejected its application for the SEDASYS® Computer-Assisted Personalized Sedation System. According to the reports, FDA sent the company a “not-approvable” letter after review of the application for, SEDASYS® which, through the use of a series of feedback and monitors, was designed to administer therapeutic levels of propofol to patients “undergoing colonoscopy and esophagoduodenoscopy procedures.”

The ASA had expressed concerns with the safety of the SEDASYS® system both in writing3 and during an FDA advisory panel hearing on the device back on May 28, 2009. However, following a presentation from the manufacturer and testimony from the public on the device, the advisory panel voted 8-2 that the device was “approvable with conditions.”4 Although reports indicate that the company will appeal the Agency’s decision, the final ruling contradicts the decision of the advisory panel and is a sound rejection of the application for the device.

In response to the news, ASA President, Dr. Alexander Hannenberg announced his strong support of the Agency’s decision and stated, “I am pleased that the FDA recognized the many unanswered questions and safety concerns about the device and the qualifications of those who sought to use it. ASA has a long history of advocating for patient safety and through its ruling on SEDASYS®, FDA has fulfilled its duty to protect patients; for that we are extremely grateful.”

  1. ASA comments to FDA
  2. FDA summary of the advisory committee meeting on May 28,2009

THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

Anesthesiologists: Physicians providing the lifeline of modern medicine. Founded in 1905, the American Society of Anesthesiologists is an educational, research and scientific association with 46,000 members organized to raise and maintain the standards of the medical practice of anesthesiology and improve the care of the patient.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists Web site at www.asahq.org. For patient information, visit LifeLineToModernMedicine.com

###

Contact:

American Society of Anesthesiologists
communications@asahq.org
847-825-5586